Top

Drug Safety

Published in:

01-09-2005 | Practical Drug Safety

Drug Treatment of Depression in HIV-Positive Patients

Safety Considerations

Authors: Andrew A. Pieper, Dr Glenn J. Treisman

Published in: Drug Safety | Issue 9/2005

Abstract

Safe and effective treatment of major depression, one of the most common comorbid conditions in individuals infected with HIV, significantly lowers morbidity and mortality from HIV disease. However, optimal treatment of both conditions is complicated by interactions between the disease processes as well as the pharmacological agents used to treat them. In patients with HIV it may be difficult to distinguish major depression from other physiological and emotional states that present with similar symptoms. Accurate diagnosis of major depression is thus complex and essential to preventing inappropriate exposure of patients to potentially harmful psychotropic medications. This review outlines important initial steps in making this diagnosis. All patients with HIV should be screened for depression by their medical providers and referred to a psychiatrist for full evaluation when necessary. The mainstay of treatment for major depression in patients with HIV disease is pharmacotherapy. Depressed patients with HIV respond to the same wide variety of antidepressant-class medications as depressed patients without HIV, including tricyclic antidepressants, paroxetine, fluoxetine and trazodone. Notably, new studies have also shown that some psychiatric medications can inhibit HIV replication.

No particular antidepressant medication is superior for the treatment of depressed HIV-infected patients; however, the most important component of treatment of major depression in HIV-disease is patient adherence, which is highly influenced by antidepressant adverse effects. This review outlines adverse effects of antidepressant-class medications that are of particular concern in HIV-infected patients and describes pharmacological strategies for overcoming these potential barriers to medication adherence. This review also describes situations in which some adverse effects of antidepressant-class medications may be safely exploited to benefit depressed patients with HIV disease. Potential interactions between antidepressant-class medications and HIV medications, as well as pharmacological treatment strategies for treating the psychiatric adverse effects of HIV medications, are also discussed.

Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001; 58: 721–8PubMedCrossRef

Kilbourne AM, Justice AC, Rabeneck L, et al. General medical and psychiatric comorbidity among HIV-infected veterans in the post-HAART era. J Clin Epidemiol 2001; 54Suppl. 1: S22–8PubMedCrossRef

Lyketsos CG, Hutton H, Fishman M, et al. Psychiatric morbidity on entry to an HIV primary care clinic. AIDS 1996; 10: 1033–9PubMedCrossRef

Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry 2001; 158: 725–30PubMedCrossRef

Dew MA, Becket JT, Sanchez J, et al. Prevalence and predictors of depressive, anxiety and substance use disorders in HIV infected and uninfected men: a longitudinal evaluation. Psychol Med 1997; 27: 395–409PubMedCrossRef

Dimatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment. Arch Intern Med 2000; 160: 2101–7PubMedCrossRef

Lenz G, Demal U. Quality of life in depression and anxiety disorders: an exploratory follow-up after intensive cognitive-behavior therapy. Psychopathology 2000; 33: 297–302PubMedCrossRef

Meltzer-Brody S, Davidson JR. Completeness of response and quality of life in mood and anxiety disorders. Depress Anxiety 2000; 12Suppl. 1: 95–101PubMedCrossRef

Holmes J, House A. Psychiatric illness predicts poor outcome after surgery for hip fracture: a prospective cohort study. Psychol Med 2000; 30: 921–9PubMedCrossRef

10.

Singh N, Squier C, Sivek C, et al. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care 1996; 8: 261–9PubMedCrossRef

11.

Hays RD, Kravitz RL, Mazel RM, et al. The impact of patient adherence on health outcomes for patients with chronic disease in the Medical Outcomes Study. J Behav Med 1994; 14: 88–90

12.

Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001; 285: 1446–74CrossRef

13.

Leserman J, Jackson ED, Petitto JM, et al. Progression to AIDS: the effects of stress, depressive symptoms, and social support. Psychosom Med 1999; 61: 397–406PubMed

14.

Leserman J. HIV disease progression: depression, stress, and possible mechanisms. Biol Psychiatry 2003; 54: 295–306PubMedCrossRef

15.

Stein MD, Solomon DA, Herman DS, et al. Depression severity and drug injection HIV risk behaviors. Am J Psychiatry 2003; 160: 1659–62PubMedCrossRef

16.

Riley ED, Wu AW, Perry S, et al. Depression and drug use impact health status among marginally housed HIV-infected individuals. AIDS Patient Care STDS 2003; 17(8): 401–6PubMedCrossRef

17.

Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV epidemiology research study. JAMA 2001; 285(11): 1466–74PubMedCrossRef

18.

van Servellen G, Chang B, Garcia L, et al. Individual and system level factors associated with treatment nonadherence in human immunodeficiency virus-infected men and women. AIDS Patient Care STDS 2002; 16(6): 269–81PubMedCrossRef

19.

Tresiman GJ. AIDS education for psychiatrists. Prim Psychiatry 1999; 6: 71–3

20.

Haller DL, Miles DR. Suicidal ideation among psychiatric patients with HIV: psychiatric morbidity and quality of life. AIDS Behav 2003; 7(2): 101–8PubMedCrossRef

21.

Treisman G, Fishman M, Schwartz J, et al. Mood disorders in HIV infection. Depress Anxiety 1998; 7(4): 178–87PubMedCrossRef

22.

Angelino AF, Treisman GJ. Management of psychiatric disorders in patients infected with human immunodeficiency virus. Clin Infect Dis 2001 Sep 15; 33(6): 847–56PubMedCrossRef

23.

Perry CM, Noble S. Didanosine: an updated review of its use in HIV infection. Drugs 1999; 58: 1099–135PubMedCrossRef

24.

Rachlis A, Fanning MM. Zidovudine toxicity: clinical features and management. Drug Saf 1993; 8: 312–20PubMedCrossRef

25.

Moore RD, Fortgang I, Keruly J, et al. Adverse events from drug therapy for human immunodeficiency virus disease. Am J Med 1996; 101: 34–40PubMedCrossRef

26.

McDaniel JS, Purcell DW, Farber EW. Severe mental illness and HIV-related medical and neuropsychiatric sequelae. Clin Psychol Rev 1997; 17: 311–25PubMedCrossRef

27.

Lyketsos CJ, Fishman M, Hutton H, et al. The effectiveness of psychiatric treatment for HIV-infected patients. Psychosomatics 1997; 38: 423–32PubMedCrossRef

28.

Lyketsos CG, Hoover DR, Guccione M, et al. Changes in depressive symptoms as AIDS develops. The Multicenter AIDS Cohort Study. Am J Psychiatry 1996; 153(11): 1430–7PubMed

29.

Elliott AJ, Russo J, Roy-Byrne PP. The effect of changes in depression on health related quality of life (HRQoL) in HIV infection. Gen Hosp Psychiatry 2002; 24: 43–7PubMedCrossRef

30.

Katon W. The epidemiology of depression in medical care. Int J Psychiatry Med 1987; 17: 93–112PubMedCrossRef

31.

Schulberg HC, Block MR, Madonia MJ, et al. The usual care of major depression in primary care practice. Arch Fam Med 1997; 6: 334–9PubMedCrossRef

32.

Perez-Stable E, Miranda J, Munoz R, et al. Depression in medical outpatients: under-recognition and misdiagnosis. Arch Intern Med 1990; 150: 1083–8PubMedCrossRef

33.

Asch SM, Kilbourne AM, Gifford AL, et al. Underdiagnosis of depression in HIV: who are we missing? J Gen Intern Med 2003; 18(6): 450–60PubMedCrossRef

34.

Perkins DO, Leserman J, Stern RA, et al. Somatic symptoms and HIV infection: relationship to depressive symptoms and indicators of HIV disease. Am J Psychiatry 1995; 155(12): 1776–81

35.

Pugh K, Riccio M, Jadresic D, et al. A longitudinal study of the neuropsychiatry consequences of HIV-1 infection in gay men. II: Psychological and health status at baseline and at 12-month follow-up. Psychol Med 1994; 24: 897–904PubMedCrossRef

36.

Lyketsos CG, Hanson A, Fishman M, et al. Screening for psychiatric morbidity in a medical outpatient clinic for HIV infection: the need for a psychiatric presence. Int J Psychiatry Med 1994; 24: 103–13PubMedCrossRef

37.

Treisman G, Fishman M, Lyketsos C, et al. Evaluation and treatment of psychiatric disorders associated with HIV infection. Res Publ Assoc Res Nerv Ment Dis 1994; 72: 239–50PubMed

38.

Lyketsos CG, Treisman GJ. Psychiatric disorders in HIV-infected patients. CNS Drugs 1995; 4: 195–206CrossRef

39.

Rabkin JG, Rabkin R, Harrison W, et al. Effect of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness. Am J Psychiatry 1994; 151: 516–23PubMed

40.

Grassi B, Gambini O, Garghentini G, et al. Efficacy of paroxetine for the treatment of depression in the context of HIV infection. Pharmacopsychiatry 1997; 30(2): 70–1PubMedCrossRef

41.

Cazzullo CL, Bessone E, Bertrando P, et al. Treatment of depression in HIV-infected patients. J Psychiatry Neurosci 1998; 23(5): 293–7PubMed

42.

De Wit S, Cremers L, Hirsch D, et al. Efficacy and safety of trazodone versus clorazepate in the treatment of HIV-positive subjects with adjustment disorders: a pilot study. J Int Med Res 1999; 27(5): 223–32PubMed

43.

Kristiansen JE, Hansen JB. Inhibition of HIV replication by neuroleptics agents and their potential use in HIV infected patients with AIDS related dementia. Int J Antimicrob Agents 2000; 14(3): 209–13PubMedCrossRef

44.

Treisman GJ, Angelino AF. The Psychiatry of AIDS: a guide to diagnosis and treatment. Chapter 2: HIV and major depression. Baltimore (MD): The Johns Hopkins University Press, 2004

45.

Elliott AJ, Uldall KK, Bergam K, et al. Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive patients. Am J Psychiatry 1998; 155(3): 367–72PubMed

46.

Zisook S, Peterkin J, Goggin KJ, et al. Treatment of major depression in HIV-seropositive men. HIV Neurobehavioral Research Center Group. J Clin Psychiatry 1998; 59(5): 217–24PubMedCrossRef

47.

Rabkin JG, Wagner G, et al. Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Am J Psychiatry 1999; 156: 101–7PubMed

48.

Rabkin JG, Wagner G, Rabkin R. Effects of fluoxetine on mood and immune status in depressed patients with HIV illness. J Clin Psychiatry 1994; 55: 92–7PubMed

49.

Rabkin JG, Wagner G, Rabkin R. Effects of sertraline on mood and immune status in patients with major depression and HIV illness: an open trial. J Clin Psychiatry 1994; 55: 433–9PubMed

50.

Ferrando SJ, Rabkin JG, deMoore GM, et al. Antidepressant treatment of depression in HIV-seropositive women. J Clin Psychiatry 1999; 60: 741–6PubMedCrossRef

51.

Rothschild AJ. New directions in the treatment of antidepressant-induced sexual dysfunction. Clin Ther 2000; 22Suppl. A: A42–A51; discussion A58-61PubMedCrossRef

52.

Woodrum ST, Brown CS. Management of SSRI-induced sexual dysfunction. Ann Pharmacother 1998; 32: 1209–15PubMedCrossRef

53.

Henry JA. Epidemiology and relative toxicity of antidepressant drugs in overdose. Drug Saf 1997; 16(6): 374–90PubMedCrossRef

54.

Younai FS, Marcus M, Freed JR, et al. Self-reported oral dryness and HIV disease in a national sample of patients receiving medical care. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92: 629–36PubMedCrossRef

55.

Ferrando SJ, Goldman JD, Charness WE. Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS: improvement in affective and somatic symptoms. Gen Hosp Psychiatry 1997; 19: 89–97PubMedCrossRef

56.

Elliott AJ, Russo J, Bergam K, et al. Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone. J Clin Psychiatry 1999; 60: 226–31PubMedCrossRef

57.

Elliott AJ, Roy-Byrne PP. Mirtazapine for depression in patients with human immunodeficiency virus. J Clin Psychopharmacol 2000; 20: 265–7PubMedCrossRef

58.

Hesse LM, von Moltke LL, Shader RI, et al. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos 2001; 29: 100–2PubMed

59.

Park-Wyllie LY, Antoniou T. Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series. AIDS 2003; 17: 638–40PubMedCrossRef

60.

Fernandez F, Levy JK, Samley HR, et al. Effects of methylphenidate in HIV-related depression: a comparative trial with desipramine. Int J Psychiatry 1995; 25: 53–67CrossRef

61.

Wagner GJ, Rabkin JG, Rabkin R. Dextroamphetamine as a treatment for depression and low energy in AIDS patients: a pilot study. J Psychosom Res 1997; 42: 407–11PubMedCrossRef

62.

Wagner GJ, Rabkin R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry 2000; 61: 436–40PubMedCrossRef

63.

Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepressant treatment: an effective prescription for treatment-refractory depression. Arch Gen Psych 1983; 40: 1335–42CrossRef

64.

Neirenberg AA, Price LH, Charney DS, et al. After lithium augmentation: a retrospective follow-up of patients with antidepressant-refractory depression. J Affect Disord 1990; 18: 167–75CrossRef

65.

Stein G, Bernadt M. Lithium augmentation therapy in tricyclic-resistant depression: a controlled trial using lithium in low and normal doses. Br J Psychiatry 1993; 162: 634–40PubMedCrossRef

66.

Katona CLE, Abou-Saleh MT, Harrison DA, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 1995; 166: 80–6PubMedCrossRef

67.

Ogura C, Okuma T, Uchida Y, et al. Combined thyroid (triiodothyronine)-tricyclic antidepressant treatment in depressive states. Folia Psychiatr Neurol Jpn 1974; 28: 179–86PubMed

68.

Joffe RT, Levitt AJ, Bagby M, et al. Predictors of response to lithium and triiodothyronine augmentation of antidepressants in tricyclic non-responders. Br J Psychiatry 1993; 163: 574–8PubMedCrossRef

69.

Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158: 131–4PubMedCrossRef

70.

Berman RM, Darnell AM, Miller HL, et al. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 1997; 154: 37–43PubMed

71.

Thase ME, Blomgren SL, Birkett MA, et al. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 1997; 58: 16–21PubMedCrossRef

72.

Department of Health and Human Services (DHHS) Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents [online]. Available from URL: http://hivatis.org [Accessed 2001 Jan 1]

73.

Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000; 283: 381–90PubMedCrossRef

74.

Tseng AL, Foisy MM. Significant interactions with new antiretrovirals and psychotropic drugs. Ann Pharmacother 1999; 33: 461–73PubMedCrossRef

75.

Treisman GJ, Kaplin AI. Neurologic and psychiatric complications of antiretroviral agents. AIDS 2003; 16: 1201–15CrossRef

76.

Dresser GK, Spence JD, Bailey DG. Pharmocokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38(1): 41–57PubMedCrossRef

77.

Ouellet D, Hsu A, Qian J, et al. Effect of fluoxetine on pharmacokinetics of ritonavir. Antimicrob Agents Chemother 1998; 42(12): 3107–12PubMed

78.

Gutierrez MM, Rosenberg J, Abramowitz W. An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin Ther 2003; 25(4): 1200–10PubMedCrossRef

79.

DeSilva KE, LeFlore DB, Marston BJ, et al. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS 2001; 15: 1281–5PubMedCrossRef

80.

Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J Clin Pharmacol 2003; 43(4): 414–22PubMedCrossRef

81.

Grant I, Atkinson JH, Hesselink JR, et al. Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections: studies with neuropsychologic testing and magnetic resonance imaging [published erratum appears in Ann Intern Med 1988, 108 (3): 496]. Ann Intern Med 1987; 107: 828–36PubMed

82.

Van Gorp WG, Satz P, Hinkin C, et al. The neuropsychological aspects of HIV-1 spectrum disease. Psychiatr Med 1989; 7: 59–78PubMed

83.

McArthur JC, Sacktor N, Selnes O. Human immunodeficiency virus-associated dementia. Semin Neurol 1999; 19: 129–50PubMedCrossRef

84.

Low-Beer S, Chan K, Yip B, et al. Depressive symptoms decline among persons on HIV protease inhibitors. J Acquir Immune Defic Syndr 2000; 23: 295–301PubMed

85.

Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo controlled trial. N Engl J Med 1987; 317: 185–91PubMedCrossRef

86.

Blum MR, Liao SH, Good SS, et al. Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med 1988; 85: 189–94PubMedCrossRef

87.

Maxwell S, Scheftner WA, Kessler HA. Manic syndrome associated with zidovudine treatment [letter]. JAMA 1988; 259: 3406–7PubMedCrossRef

88.

Wright JM, Sachdev PS, Perkins RJ, et al. Zidovudine-related mania. Med J Aust 1989; 150: 339–41PubMed

89.

O’Dowd MA, McKegney FP. Manic syndrome associated with zidovudine [letter]. JAMA 1988; 260: 3587–8CrossRef

90.

SUSTIVATM (efavirenz) capsules [US prescribing information]. Wilmington (DE): DuPont Pharmaceuticals Company, 2000

91.

Colebunders R, Verdonck K. Reply to Gonzalex and Everall. Lest we forget: neuropsychiatry and the new generation anti-HIV drugs [letter]. AIDS 1999; 13: 869PubMedCrossRef

92.

Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341: 1865–73PubMedCrossRef

93.

Moyle G. Efavirenz: practicalities, considerations and new issues. Int J Clin Pract Suppl 1999; 103: 30–4PubMed

94.

Hawkins T, Grossman D, Haubrich R. CNS side effects of EFV may persist in patients thought to tolerate the drug [abstract WePpB1376]. XIII International Conference on AIDS; 2000 Jul 9-14; Durban.

95.

Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients. AIDS 2001; 15: 71–5PubMedCrossRef

Title: Drug Treatment of Depression in HIV-Positive Patients
Safety Considerations
Authors: Andrew A. Pieper
Dr Glenn J. Treisman
Publication date: 01-09-2005
Publisher: Springer International Publishing
Published in: Drug Safety / Issue 9/2005
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI: https://doi.org/10.2165/00002018-200528090-00002

At a glance: The STEP trials

Springer Medicine

Drug Treatment of Depression in HIV-Positive Patients

Safety Considerations

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2005

Physicians’ Attitudes and Adverse Drug Reaction Reporting

The Role of P-Glycoprotein and Organic Anion-Transporting Polypeptides in Drug Interactions

Computer Calculated Dose in Paediatric Prescribing

When Should Vaccination Be Contraindicated in Children?

Drug-Induced Hypomagnesaemia

A Comparison of Reported Gastrointestinal and Thromboembolic Events Between Rofecoxib and Celecoxib Using Observational Data